Xeris Biopharma Holdings Inc (XERS)
2.87
+0.04
(+1.41%)
USD |
NASDAQ |
Sep 27, 16:00
2.87
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Research and Development Expense (Annual): 22.34M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.34M |
| December 31, 2022 | 20.97M |
| December 31, 2021 | 25.16M |
| December 31, 2020 | 20.92M |
| Date | Value |
|---|---|
| December 31, 2019 | 60.44M |
| December 31, 2018 | 40.65M |
| December 31, 2017 | 20.17M |
| December 31, 2016 | 10.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
20.92M
Minimum
2020
60.44M
Maximum
2019
29.97M
Average
22.34M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Zoetis Inc | 614.00M |
| Zevra Therapeutics Inc | 39.81M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 5.185M |